Stoneridge is two bets welded together. One is a consensus cyclical recovery play you can buy cheaper elsewhere. The other is a first-mover camera mirror product with no direct competitor, growing 69% YoY, buried inside a company the market is pricing for distress. The question is whether the second bet justifies owning the first.

The Setup

SRI just guided 2026 EBITDA to $22.5M — lower than 2025's $28.6M — while simultaneously announcing the CEO and CFO are both departing. Q1 is guided to breakeven. The credit facility got a 16-month band-aid extension to July 2027. Covenant headroom is 29 basis points.

The stock responded appropriately: down 34% in a month to $5.79, RSI 21.

What makes this interesting rather than just ugly is what's happening underneath.

MirrorEye: The Idiosyncratic Thesis

MirrorEye replaces traditional truck side-view mirrors with cameras and in-cab displays. Three value propositions for fleet operators: improved safety (eliminates blind spots), better fuel economy (reduced aerodynamic drag), and driver comfort. Revenue went from near-zero five years ago to $111M in 2025 (+69% YoY), guided to $160M+ in 2026 (+45%). OEM programs are live with Daimler and Volvo in North America, European OEMs are ramping, and bus programs grew 34%.

We searched for direct competitors in commercial truck exterior camera mirror systems. Found none at scale. indie Semiconductor confirmed CMS design wins with Tier 1s for production beginning late 2026 — validating that OEMs are investing in the category — but no other company is shipping a competing product on Class 8 trucks today. Gentex's Full Display Mirror is a different market entirely (interior rearview for passenger cars). SRI appears to be genuinely alone in this niche.

The company secured the "largest business award in Stoneridge history" for a MirrorEye OEM program extension, part of $830M in total lifetime revenue awards in 2025. Management says take rates are "improving" in Europe and North America but won't disclose specifics. That opacity cuts both ways — it means the market can't model the upside, but it also means we can't verify the growth trajectory independently.

This is the only factor that's specific to SRI and not available through any other equity. If MirrorEye adoption is faster or bigger than the market expects, that alpha flows exclusively through SRI.

What's NOT Edge: The CV Cycle

Management described 2025 as having "some months that set all-time record lows for actual orders placed in commercial vehicle space." We corroborated this across 10+ companies spanning the entire CV supply chain: Cummins confirmed NA heavy/medium-duty down 30%. PACCAR reported 233,000 Class 8 retail units in a "soft freight" environment. Rush Enterprises (largest NA truck dealer) confirmed a five-to-six month order drought that only broke in December. NN Inc said February 2026 orders were "highest ever for this time of year."

The consensus on recovery timing is remarkably uniform: H1 2026 weak, H2 2026 recovery driven by EPA 2027 pre-buy. Atmus Filtration quantified the catalyst: $10,000-15,000 incremental cost per truck for NOx compliance, forcing fleets to order ahead of the regulatory deadline.

This is important context for SRI, but it is not edge. Every CV supplier on earth is presenting the same slide deck. SRI's guidance actually assumes flat end markets while third-party forecasters project +7-10%. That conservatism creates built-in upside, but the upside belongs to the sector, not to SRI specifically. If the thesis is "CV cycle at trough," buy PACCAR — better balance sheet, higher liquidity, beta of 1.05 vs SRI's 1.46, down only 9% instead of 34%.

Factor Decomposition

This is where the picture sharpens. SRI's idiosyncratic variance is 66.6% — below the 75% target. A third of the stock's movement is market beta before we even subtract sector exposure.

Estimated variance attribution:

Edge-driven variance: roughly 40%. That's the MirrorEye thesis plus a contrarian view on the governance discount.

The 1-month price action confirms this decomposition. PCAR, CMI, and ALSN fell 4-11% in the same period. SRI fell 34%. The ≈10% shared decline is sector. The remaining 25% gap is idiosyncratic — the market pricing the dual C-suite departure, the EBITDA step-down, and the covenant tightness. That idiosyncratic selloff is either an overreaction to temporary noise (bull case) or appropriate risk pricing for a company entering a valley year without a permanent CFO (bear case).

The Governance Question

Both the CEO and CFO departing simultaneously is unusual. Zizelman (CEO) out April 1, Horvath (CFO) out March 31. The new CEO is Natalia Noble, who spent two years as President of Electronics — the division that IS the MirrorEye story. She led the product through its 69% growth year. That's the right person for the bull thesis. The CFO replacement is Bob Hartman, the Chief Accounting Officer, in an "interim" capacity. No permanent CFO search timeline was disclosed.

Five executives — including the departing CEO and CFO — bought shares on March 2 at approximately $5.79. Ten days before the earnings call. They knew what was coming and bought anyway.

The insider buying is real signal. But interim CFO during a refinancing year is real risk.

The Credit Constraint

Leverage stands at 3.46x against a 3.75x covenant. Twenty-nine basis points of cushion. The credit facility expires July 2027.

2025 free cash flow of $19M sounds fine until you realize $18.7M of it was inventory liquidation. That's not repeatable. With 2026 EBITDA declining to $22.5M and inventory near the floor, 2026 FCF is uncertain — management didn't provide guidance. If EBITDA hits guidance and capex runs $12-15M, free cash flow is thin. If Q1 comes in below breakeven, the leverage ratio spikes and covenant breach risk becomes real.

The most likely outcome is they muddle through — the CD divestiture proceeds already reduced debt, and the covenant is designed with some flex. But "most likely to muddle through" is not the same as "safe." This is a binary tail risk: either they refinance and the survival discount evaporates, or they breach and the equity gets restructured.

Scenarios and Forward EV (12 months)

Current enterprise value is approximately $260M ($160M equity + ≈$100M estimated net debt post-CD sale).

Probability-weighted return: +56%.

The entire edge sits in the right tail. We assign 20% to beat-and-raise where the market likely prices 10%. The gap exists because: (1) MirrorEye has no comp set for the market to model, (2) guidance explicitly assumes flat end markets vs +7-10% industry consensus, (3) insider buying at current levels, and (4) CV cycle direction is certain — only timing is variable.

The market-implied probability distribution (which recovers the current $260M EV) is approximately 15% distress, 40% slow, 35% on-track, 10% beat. The divergence is modest, not dramatic.

After applying the 40% edge adjustment (only MirrorEye and governance are idiosyncratic), annualized idiosyncratic alpha is approximately 6.6%. Real but not exciting. Within the 5-15% realistic range, toward the low end.

What Resolves This

May 6 — Q1 2026 earnings. That single data point answers four questions simultaneously:

1. Is breakeven EBITDA real, or did they miss? (covenant risk)
2. What's MirrorEye's quarterly run-rate tracking? (growth thesis)
3. Is there a permanent CFO plan? (governance)
4. Any early signal on H2 order books? (cycle timing)

Beyond Q1, the monthly ACT Research Class 8 order data and H2 2026 pre-buy activity will confirm or deny the cyclical recovery in real time. By Q3 2026, the pattern collapses — you'll know if this is a MirrorEye growth story trapped in a valley year, or a levered cyclical that can't get out of its own way.

The Thesis in Plain Terms

This is interesting at current levels if — and only if — you're buying the MirrorEye story specifically. The 10th percentile path is $3.00-3.50 on covenant breach. The bear case is survivable if sized accordingly.

Without a MirrorEye-specific thesis, this is just a leveraged CV cycle bet with governance risk, and PACCAR is the cleaner vehicle.

What Changes the Math

Any two of these shift edge-driven variance from 40% to 55%+ and make the idiosyncratic thesis substantially stronger:

• MirrorEye take rate disclosure (market can model the upside)
• Permanent CFO hire (governance discount removed)
• Credit facility refinanced (survival risk eliminated)
• Q1 EBITDA beats breakeven (hockey stick becomes credible)

Until then, the edge is real but modest — 6.6% annualized idiosyncratic alpha at 40% edge-driven variance. If the thesis is right, there will be time to add as data confirms it.

Evidence